New combo therapy shows promise for rare leukemia patients

NCT ID NCT03410875

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, vemurafenib (a pill) and obinutuzumab (an infusion), in 30 people with previously untreated hairy cell leukemia. The goal is to see how many patients achieve a complete response, meaning no signs of cancer after treatment. Participants take vemurafenib for 4 months and receive obinutuzumab infusions starting in the second month. The study is currently active but no longer recruiting new participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hairy cell leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAIRY CELL LEUKEMIA LEUKEMIA LEUKEMIA, HAIRY CELL

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Yale University

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.